Taysha Gene Therapies Issues Inducement Grants to Four New Hires
Taysha granted RSUs and stock options to four new employees as inducements under its 2023 Inducement Plan and Nasdaq listing rules.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Board of Directors' Compensation Committee approved equity awards for four newly hired employees, effective October 1, 2026, as part of standard recruitment incentives authorized under Nasdaq Listing Rule 5635(c)(4).
The grants consist of restricted stock units representing 384,000 shares of Taysha common stock, along with a stock option covering 92,400 shares. Both instruments were issued under the company's 2023 Inducement Plan, a vehicle specifically designed to attract talent without requiring shareholder approval under the applicable Nasdaq exception.
Read more Adapt Launches AI Late Pay Agent to Automate Payment Collection →
Dallas-based Taysha focuses on developing adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. The company remains in the clinical stage, making competitive equity compensation a key tool for recruiting specialized scientific and operational talent in a competitive biotechnology labor market.
Inducement grants of this type are a common mechanism among clinical-stage biotechs, allowing companies to extend equity-linked compensation to incoming employees outside of existing shareholder-approved equity plans, as long as the awards qualify under Nasdaq's listing standards.
Continue reading at GlobeNewswire - Industry News on Financial Services
